Related Experiment Video
Updated: Jun 25, 2025

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique
Published on: January 14, 2016
KBTBD4 Cancer Hotspot Mutations Drive Neomorphic Degradation of HDAC1/2 Corepressor Complexes
Abstract:
Cancer mutations can create neomorphic protein-protein interactions to drive aberrant function 1 . As a substrate receptor of the CULLIN3-RBX1 E3 ubiquitin ligase complex, KBTBD4 is recurrently mutated in medulloblastoma (MB) 2 , the most common embryonal brain tumor in children, and pineoblastoma 3 . These mutations impart gain-of-function to KBTBD4 to induce aberrant degradation of the transcriptional corepressor CoREST 4 . However, their mechanism of action remains unresolved. Here, we elucidate the mechanistic basis by which KBTBD4 mutations promote CoREST degradation through engaging HDAC1/2, the direct neomorphic target of the substrate receptor. Using deep mutational scanning, we systematically map the mutational landscape of the KBTBD4 cancer hotspot, revealing distinct preferences by which insertions and substitutions can promote gain-of-function and the critical residues involved in the hotspot interaction. Cryo-electron microscopy (cryo-EM) analysis of two distinct KBTBD4 cancer mutants bound to LSD1-HDAC1-CoREST reveals that a KBTBD4 homodimer asymmetrically engages HDAC1 with two KELCH-repeat propeller domains. The interface between HDAC1 and one of the KBTBD4 propellers is stabilized by the MB mutations, which directly insert a bulky side chain into the active site pocket of HDAC1. Our structural and mutational analyses inform how this hotspot E3-neo-substrate interface can be chemically modulated. First, our results unveil a converging shape complementarity-based mechanism between gain-of-function E3 mutations and a molecular glue degrader, UM171. Second, we demonstrate that HDAC1/2 inhibitors can block the mutant KBTBD4-HDAC1 interface, the aberrant degradation of CoREST, and the growth of KBTBD4-mutant MB models. Altogether, our work reveals the structural and mechanistic basis of cancer mutation-driven neomorphic protein-protein interactions and pharmacological strategies to modulate their action for therapeutic applications.
Insights
Cancer mutations in KBTBD4 drive medulloblastoma by causing aberrant degradation of CoREST. This study reveals how mutations create new interactions with HDAC1/2, offering therapeutic targets for pediatric brain tumors.
Area of Science:
- Oncology
- Structural Biology
- Molecular Biology
Background:
- Recurrent mutations in KBTBD4, a substrate receptor for the CULLIN3-RBX1 E3 ubiquitin ligase, are found in medulloblastoma (MB) and pineoblastoma.
- These mutations lead to gain-of-function, promoting the aberrant degradation of the transcriptional corepressor CoREST, but the mechanism remains unclear.
Purpose of the Study:
- To elucidate the mechanism by which KBTBD4 mutations promote CoREST degradation.
- To identify the specific interactions between KBTBD4 mutants and their neomorphic target, HDAC1/2.
- To explore therapeutic strategies targeting the aberrant KBTBD4-HDAC1 interaction.
Main Methods:
- Deep mutational scanning to map the KBTBD4 mutation landscape.
- Cryo-electron microscopy (cryo-EM) to determine the structure of KBTBD4 mutants bound to LSD1-HDAC1-CoREST.
- In vitro assays and medulloblastoma models to test therapeutic interventions.
Main Results:
- KBTBD4 mutations promote CoREST degradation by engaging HDAC1/2.
- Structural analysis revealed KBTBD4 forms a homodimer that binds HDAC1, with mutations stabilizing this interface.
- Gain-of-function mutations were mapped, showing specific preferences for insertions and substitutions.
- Molecular glue UM171 and HDAC1/2 inhibitors were found to disrupt the mutant KBTBD4-HDAC1 interaction and inhibit tumor growth.
Conclusions:
- Elucidated the mechanistic basis of cancer mutation-driven neomorphic protein-protein interactions involving KBTBD4, HDAC1/2, and CoREST.
- Demonstrated that HDAC1/2 inhibitors can block the mutant KBTBD4-HDAC1 interaction, CoREST degradation, and KBTBD4-mutant MB growth.
- Identified potential therapeutic strategies targeting the aberrant E3-neo-substrate interface for pediatric brain tumor treatment.
Related Concept Videos
Histone Variants at the Centromere
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Abnormal Proliferation
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Cancers Originate from Somatic Mutations in a Single Cell
Induced Pluripotent Stem Cells
Somatic...

